8-KLeadership Changes

ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Executive Changes (Mar 8, 2023)

Filed March 8, 2023For Securities:ALNY

Summary

Alnylam Pharmaceuticals, Inc. (ALNY) announced a change to its Board of Directors through a Form 8-K filing on March 8, 2023. The company expanded its board size from twelve to thirteen members and elected Peter N. Kellogg as a new Class II director. Mr. Kellogg's term will expire at the 2024 annual meeting of stockholders, and he is expected to join the Audit Committee, a critical oversight function for financial reporting and internal controls. This appointment brings new expertise to the board, and the filing details Mr. Kellogg's compensation package, which includes an annual cash fee and a significant stock option grant. This compensation structure aligns with standard practices for non-employee directors and aims to incentivize long-term value creation for shareholders. Investors should note the addition of a director and the associated compensation as a governance-related event.

Key Highlights

  • 1Alnylam Pharmaceuticals expanded its Board of Directors from twelve to thirteen members.
  • 2Peter N. Kellogg was elected as a new Class II director, with his term expiring at the 2024 annual stockholder meeting.
  • 3Mr. Kellogg is expected to be appointed to the Audit Committee, enhancing board oversight.
  • 4As a non-employee director, Mr. Kellogg will receive an annual cash fee of $55,000, increasing to $60,000 from April 1, 2023.
  • 5Mr. Kellogg received a stock option grant with a grant date fair value of $600,000, vesting ratably over three years.
  • 6Future annual stock option awards for Mr. Kellogg are expected to have a grant date fair value of $400,000, vesting in one year.
  • 7Mr. Kellogg will enter into a standard indemnification agreement with the company.

Frequently Asked Questions

The company expanded its Board of Directors from twelve to thirteen members to fill a newly created vacancy with the election of Peter N. Kellogg, who is expected to bring valuable experience to the board.

Mr. Kellogg will receive an annual cash fee of $55,000 (increasing to $60,000 from April 1, 2023). He was also granted a stock option to purchase 4,948 shares with a grant date fair value of $600,000, vesting over three years. He will be eligible for future annual stock option awards valued at $400,000, vesting in one year.

An appointment to the Audit Committee is significant as this committee plays a crucial role in overseeing the company's financial reporting, internal controls, and audit processes, providing an important layer of corporate governance and investor assurance.

The initial stock option grant of $600,000 vests ratably in three annual installments, starting on the one-year anniversary of the grant date. Future annual stock option awards are expected to vest in full on the one-year anniversary of their grant date.